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The study was made to evaluate bone turnover in systemic lupus erythematosus (SLE) patients
undergoing long-term glucocorticoid therapy. Thirty-eight female patients with established SLE
were compared with a control group consistingfrom 160 age-matched healthy women. Serum con-
centrations ofproinflammatory cytokines: interleukin-la, interleukin-6, tumor necrosis factor-oc
granulocyte-macrophage colony stimulating factor (GM-CSF) and some biochemical markers of
osteoporosis (osteocalcin, total and bone alkalinephosphatase, procollagen type Icarboxyterminal
propeptide, carboxyterminal telopeptides of type I collagen - CTx) were measured. Additionally,
morning urine excretions ofdeoxypyridinoline and calcium/creatinin ratios were determined. The
forearm densitometry (DXA) wasperformed in allpatients. Bone mineral content (BMC) and bone
mineral density (BMD) in the SLE group was not significantly differentfrom the controls, and no
relationship was found between the glucocorticoid exposure and the BMC/BMD. However, bio-
chemical markers of bone resorption - CTx and calcium/creatinin ratio - were significantly
increased in thepatient group. Our results suggest thatBMD/BMC is preserved in glucocorticoid-
treated SLEpatients despite accelerated bone turnover.
INTRODUCTION
Systemic Lupus Erythematosus (SLE)b
is a chronic, inflammatory disease charac-
terized by a wide range of immunological
changes and autoimmune phenomena [1,
2]. Glucocorticoids (gcs) still remain the
first-choice treatment option for SLE.
They possess strong anti-inflammatory
and immunosuppressive properties, main-
ly due to their profound effect on the pro-
duction of proinflammatory cytokines [3-
5]. Although very effective, gcs treatment
causes a number of adverse events. For
instance, gcs have an inhibitory effect on
the bone turnover and may induce osteo-
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porosis, delay healing of fractures, inhibit
bone growth, and cause osteonecrosis via
reduction of osteoblast activity [4, 6, 7].
The risk of glucocorticoid-induced osteo-
porosis may be especially high in patients
who need long-term, high-dose gcs treat-
ment, like those with SLE. The aim of the
study presentedhere wastoevaluatethebone
tissue metabolism in SLE patients based on
the measurement of biochemical markers
ofosteoporosis and densitometry results in
relation to the glucocorticoid exposure.
MATERIALS
Patients: Thirty-eight female patients
with established SLE treated with gcs (age
46.4 ± 12.8 years, disease duration 108 +
82 months; total gcs dose equivalent to
prednisone 25.3 ± 28.1 g per patient, dura-
tion of treatment 90.8 ± 78.5 months; all
values are mean ± SD) The control group
consisted of 160 healthy women (age 52 ±
12 years). Sixteen patients (age 35.9 ± 10
years; disease duration 82 ±69months; total
dose of gcs-equivalent to prednisone 14.7
± 12.6 gperpatient) and 58 healthy controls
(age 42 ± 10 years) were premenopausal.
Twenty-two patients (age 53.9 ± 8.5 years,
disease duration 126 ± 87 months, total
dose of gcs- equivalent to prednisone 33.1
± 33.6 g per patient) and 102 controls (age
52 ± 8 years) were postmenopausal. Beside
gcs, 10 patients were treated with cyclo-
phosphamide, four of them orally (50 to
100 mg daily), and six of them intra-
venously (800 mg every 4th to 8th week).
One patient received azathioprine (100 mg
perday orally). Twenty-four ofSLEpatients
were treated with non-steroidal anti-inflam-
matory drugs. SLE patients and healthy
subjects who underwentestrogen, calcitonin
orbisphosphonate therapy were notincluded.
Laboratory tests: Blood samples were
taken from all subjects in fasting condition,
without anticoagulants, centrifuged, and
stored at -70° C. Urine samples were
obtained after a 24-hour calcium- and col-
lagen-free diet, centrifuged, and stored at
-70° C.
Serum levels ofacute-phase reactants:
ca-l-acid-glycoprotein (AGP) and a-i-
chymotrypsine (ACT) were measured by
rocket immunoelectrophoresis [8]. Glyco-
sylation profile of a-l-acid-glycoprotein
was determined using affinity immuno-
electrophoresis with the lectin con-
canavalin A as described by B0g-Hansen
[9] and the results were expressed as reac-
tivity coefficients (AGP-RC). Bone isoen-
zyme of alkaline phosphatase (AP-B),
deoxypyridynoline (Dpd), osteocalcin
(BGP), and carboxy-terminal propeptide
of type 1 collagen (PIPC) were measured
by ELISA using commercially available
kits (Alkphase-B, Pyrilinks-D, Novocalcin
and Prolagen-C, respectively) obtained
from Metra Biosystems (USA). Serum lev-
els ofcarboxy-terminal collagen crosslinks
(CTx) were measured with Serum
CrossLaps One Step ELISA kits from
Osteometer Biotech (Denmark). Serum
tumor necrosis factor-a (TNF-a), inter-
leukin-6 (IL-6), interleukin-loc (IL-la),
and granulocyte/monocyte colony stimu-
lating factor (GM-CSF) were measured by
ELISA using the Quantikine kit purchased
from R&D System (USA).
Densitometry: The bone mineral den-
sity (BMD) and bone mineral content
(BMC) of the forearm were measured
using standard DXAtechnique (DTX-200,
Osteometer, Denmark).
Statistical analysis: The Mann-Whitney
U, the Kruskal-Wallis ANOVA, and the
Fisher's exact test were used to compare
variables (differences wereconsidered signif-
icant at p < .05). To determine the correla-
tion between the variables the Spearman
test was used (results were consider posi-
tive for r > 0.5 at p < .05).Korczowska etal.: Glucocorticoids, bone metabolism, and systemic lupus 47
RESULTS
The differences in BMC and BMD
between SLE patients and age-matched
healthy controls were not statistically sig-
nificant (Table 1). We found eight SLE
patient with osteoporosis (age, 60.3 ± 9.4
years) and 22 woman with osteoporosis in
healthy group (63.5 ± 6.5 years), but there
were no differences in BMC and BMD
between this two group.
The BMC and BMD were decreased
in postmenopausal women in eitherpatient
and control groups (Table 2). Because of
correlation between BMC and age of
menopause the changes in BMC depend-
ing on age have been analyzed in the group
of SLE patients and healthy subjects. The
correlation between BMC and age suggests
faster bone loss in SLE patients, however
it was not found to be statistically signifi-
cant (Figure 1).
Table 1. Bone mineral content (BMC) and bone mineral density (BMD) in systemic
lupus erythematosus (SLE) patients treated with glucocorticoids and in the control
group, (all values are mean ± SD).
SLE Control group
BMC 2.888 + 0.584 2.901 + 0.501
(g) (1.613 - 4.368) (1.788 - 5.160)
BMC -1.0 ± 1.2 -0.9 ± 1.0
T-score (-3.7 - 2.2) (-3.3 - 1.9)
BMD 0.423 + 0.080 0.427 ± 0.065
(g/cm2) (0.239 - 0.594) (0.238 - 0.639)
BMD -1.2 ± 1.4 -1.1 + 1.1
T-score (-4.3 - 1.8) (-4.3 - 1.3)
* - Statistically significant vs. control group (p < .01)
- Statistically significant vs. control group (p < .05)
Table 2. Bone mineral content (BMC) and bone mineral density (BMD) in systemic
lupus erythematosus (SLE) patients and in the control group before (Menop-) and
after menopause (Menop+), (all values are mean ± SD).
SLE Control group
Menop- Menop+ Menop- Menop+
BMC 3.086 + 0.377 2.762 + 0.661 # 3.103 + 0.459 2.781± 0.489
(g) (2.494 - 3.880) (1.613 - 4.368) (2.360 - 5.160) (1.788 - 3.913)
BMC -0.6 ± 0.8 -1.2 + 1.4 -0.54 + 0.81 -1.2 ± 1.0
T-score (-1.8 - 1.2) (-3.7 - 2.2) (-2.1 - 1.9) (-3.3 - 1.3)
BMD 0.466 + 0.046 0.395 + 0.085 * 0.456 + 0.050 0.408 ± 0.065 #
(g/cm2) (0.404 - 0.579) (0.239 - 0.594) (0.378 - 0.639) (0.238 - 0.566)
BMD -0.4 ± 0.8 -1.7 ± 1.5* -0.57 + 0.78 -1.4 ± 1.1
T-score (-1.5 - 1.5) (-4.3 - 1.8) (-1.9 - 1.3) (-4.3 - 1.3)
* - Statistically significant vs. group before menopause (p < .01)
- Statistically significant vs. group before menopause (p < .05)48 Korczowska etal.: Glucocorticoids, bone metabolism, andsystemic lupus
Figure 1. Correlation between bone mineral content (BMC) and the age in post-
menopausal patients after menopause and controls.
Figure 2. The correlation between the levels of carboxy - terminal collagen
crosslinks (CTx) and interleukin 6 (IL-6) in SLE patients and in the control.
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Table 3. The level of erythrocyte sedimentation rate (ESR), al-acid-glycoprotein
(AGP), al-acid-glycoprotein-reactivity-coefficient (AGP-RC) and a-chymotripsine
(ACT), antibodies to dsDNA and C3, C4 complement in systemic lupus erythemato-
sus (SLE) patients and in the control group, (all values are mean ± SD).
SLE Control group
ESR 41 +30* 10+4
(mm/h) (4- 138) (4- 18)
AGP 1717 + 811 * 696 + 299
(mg/I) 195 - 4040) (351 - 1386)
AGP-RC 1.16 + 0.33 1.31 + 0.24
(0.70 - 2.30) (1.00 - 1.70)
ACT 677 +360 # 303 + 81
(mg/I) (166 - 2028) (189 - 420)
dsDNA 392 + 479* 23 + 24
(lU/ml) (33 - 1925) (0 - 72)
C3 1226 +318 1148 +257
(mg/I) (653 - 1848) (696 - 1695)
C4 176 +81# 243 +69
(mg/I) (55 - 372) (117 - 360)
* - Statistically significant vs. control group (p < .01)
- Statistically significant vs. control group (p < .05)
Table 4. The levels of cytokines: interleukin la (IL-la), interleukin 6 (IL-6), tumour
necrosis factor alpha (TNF-a) and granulocyte-macrophage colony stimulating fac-
tor (GM-CSF) in systemic lupus erythematosus (SLE) patients and in the control
group, (all values are mean ± SD).
SLE Control group
IL-1a 1.9 + 2.4 0.7± 1.3
(pg/mI) (0.0 - 12.5) (0.0 - 3.8)
IL-6 20.4 + 30.6 * 1.6 + 2.0
(pg/mI) (3.1 - 146.7) (0.0 - 5.8)
TNF-a 8.1 ±5.2 * 1.3+2.0
(pg/mI) (2.6 - 29.2) (0.0 - 5.4)
GM-CSF 1.7 + 1.2 0.8
± 1.2
(pg/mI) (0.0 -3.8) (0.0 -3.7)
* - Statistically significant vs. control group (p < .01)
- Statistically significant vs. control group (p < .05)50 Korczowska etal.: Glucocorticoids, bone metabolism, and systemic lupus
Serum levels of acute phase proteins
are shown on Table 3. In the SLE group,
increase in the IL-6 and TNF-a levels was
observed. The levels of other cytokines
were similar in patients andcontrols (Table
4). No significant differences were found
between the patients and the healthy con-
trols in the levels of BGP, AP and AP-B.
Two markers ofbone resorption (CTx and
Ca/Crearatio) were significantly increased
in SLE compared to control subjects
(Table 5). The differences in pre- and post-
menopausal patients are shown on Table 6.
We divided our patients with SLE into
three groups: eight with osteoporosis, 15
with osteopenia, and 15 without osteo-
porosis and osteopenia. Two markers of
bone metabolism (AP-B and Dpd) and
serum levels of IL-6 were significantly
increased in SLE with osteoporosis com-
pared to SLE without osteoporosis and
osteopenia (Table 7).
Statistically significant correlation
between total dose of gcs and the BMC
was not observed (r = -0.065, NS).
However, statistically significant correla-
tion were observed between the levels of
CRPand CTx (r= 0.244, p < .01) andAGP
and CTx (r = 0.272; p < .01). There were
also statistically significant correlation
between CTx and IL-6 (Figure 2), CTx and
BGP, and the AP-B activity and the BGP
level in the group of SLE patients and the
control group (Figure 3).
Table 5. The levels of markers of bone tissue metabolism: osteocalcin (BGP), alka-
line phosphatase (AP) and alkaline phosphatase-bone formation (AP-B), procollagen
type I carboxyterminal propeptide (PIPC), carboxyterminal telopeptides of type I col-
lagen (CTx), deoxypyridynoline (Dpd) and calcium/creatinin ratio (CalCrea) in sys-
temic lupus erythematosus (SLE) patients and in the control group, (all values are
mean ± SD).
SLE Control group
BGP 6.8 + 3.7 6.5 + 3.7
(ng/ml) (1.2 - 21.0) (1.2 - 13.8)
AP 105±71 92+27
(UI) (21 - 192) (31 - 146)
AP-B 29.4 ± 14.8 24.0 ± 11.5
(UA) (11.7 -68.5) (7.0 -55.7)
PICP 118 + 55 105 + 40
(ng/ml) (70 - 241) (48 - 166)
CTx 3380 + 2541 # 2390 ± 1360
(pM) (598 - 10231) (1146 - 5975)
Dpd 7.7 ± 4.8 6.5 ± 1.6
(nM) (1.0 - 19.0) (4.2 - 9.0)
CalCrea 0.31 +0.20 0.22 ± 0.11
(0.08 - 0.66) (0.05 - 0.44)
*- Statistically significant vs. control group (p < .01)
- Statistically significant vs. control group (p < .05)Korczowska et al.: Glucocorticoids, bone metabolism, and systemic lupus 51
Figure 3. The correlation between the levels of following biochemical markers of
osteoporosis: carboxy - terminal collagen crosslinks (CTx), bone alkaline phos-
phatase (AP-B), and osteocalcin (BGP) in systemic lupus erythematosus (SLE)
patients and in the control.
Table 6. The levels of osteocalcin (BGP), alkaline phosphatase (AP) and alkaline
phosphatase-bone formation (AP-B), procollagen type I carboxyterminal propeptide
(PIPC), carboxyterminal telopeptides of type I collagen (CTx), deoxypyridynoline
(Dpd) and calcium/creatinin ratio (Ca/Crea) in systemic lupus erythematosus (SLE)
patients and in the control group before (Menop-) and after menopause (Menop+),
(all values are mean ± SD).
SLE Control group
Menop- Menop+ Menop- Menop+
BGP 6.0 ± 2.7 7.3 ± 4.2 5.6 ± 3.6 7.8 ± 3.6
(ng/ml) (1.3 - 9.8) (1.2 - 21.0) (1.2 - 11.0) (3.2 - 13.8)
AP 81 ±28 122±86 87±29 106±18#
(U/A) (21 - 145) (64 -473) (31 - 146) (89 - 133)
AP-B 24.2± 11.9 33.1 ± 15.8 26.2±11.5 30.5± 11.6#
(U/A) (12.1 - 56.9) (11.7 - 68.5) (7.0 - 42.5) (18.4 - 55.7)
PICP 74±6 133±56# 88±38 124±37#
(ng/ml) (70 - 78) (85 - 241) (48 - 150) (80 - 166)
CTx 3862 ±3072 3086 ±2200 1660 ±426 3241 ± 1615#
(pM) (978 - 10231) (598 - 8641) (1146 - 2166) (1560 - 5975)
Dpd 4.3 ± 3.5 9.2 ± 4.5 # 5.4 ± 1.3 7.6 ± 1.0 #
(nM) (1.0 - 10.0) (4.0 - 19.0) (4 - 7) (7.0 - 9.0)
Ca/Crea 0.4 ± 0.27 0.28 ± 0.18 0.17 ± 0.11 0.25 ± 0.10
(0.13 - 0.66) (0.08 - 0.59) (0.05 - 0.43) (0.05 - 0.44)
* - Statistically significant vs. group before menopause (p < .01)
- Statistically significant vs. group before menopause (p < .05)
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Table 7. The levels of interleukin la (IL-la), interleukin 6 (IL-6), tumour necrosis fac-
tor alpha (TNF-a) and granulocyte-macrophage colony stimulating factor (GM-CSF)
osteocalcin (BGP), alkaline phosphatase (AP) and alkaline phosphatase-bone for-
mation (AP-B), carboxyterminal telopeptides of type I collagen (CTx), deoxypyri-
dynoline (Dpd) and calcium/creatinin ratio (Ca/Crea) in systemic lupus erythemato-
sus (SLE) patients with osteoporosis, with osteopenia and with without osteoporosis
and osteopenia (all values are mean ± SD).
SLE SLE SLE without osteoporosis
with osteoporosis with osteopenia and osteopenia
IL-1 1.4 ± 1.3 3.1 ±3.3 1.0 ± 1.7
(pg/mI) (0.0 - 3.3) (0.0 - 12.5) (0.0 - 5.8)
IL-6 42.2 ± 52.4 # 18.7 ± 27.3 10.8 + 9.7
(pg/mI) (3.7 - 146.7) (3.1 - 97.4) (3.1 - 37.0)
TNF 9.4 ± 4.9 8.7 + 6.7 6.4 ± 2.9
(pg/mI) (5.7 - 18.5) (4.8 - 29.2) (2.6 - 12.4)
GM-CSF 1.9 + 1.3 1.2 ±0.8 2.3 + 1.1
(pg/mI) (1.0 - 3.8) (0.0 - 2.3) (1.2 - 3.8)
BGP 10.2 +4.9 5.8+3.6 7.1 ±3.7
(ng/ml) (6.0-21.0) (1.2- 11.9) (2.1 - 15.6)
AP 112±41 92±20 91 ±23
(U/I) (70 - 192) (64 - 151) (21 - 138)
AP-B 40.7 ± 18.9* 19.9 ± 7.1 21.2 ± 7.9
(U/I) (18.3 - 68.5) (11.7 - 37.9) (12.2 - 40.0)
CTx 4141 ±3068 2805 ±3119 3670 ±2387
(pM) (732 - 8641) (665 - 10231) (598 - 7655)
Dpd 12.1 ±0.97* 6.2 ±3.4 7.8 ±4.9
(nM) (2.0 - 19.0) (2.7 - 9.8) (1.0 - 13.3)
Ca/Crea 0.31 ± 0.20 0.25 ± 0.20 0.28 ± 0.14
(0.08 - 0.46) (0.02 - 0.66) (0.14 - 0.25)
* - Statistically significant vs. group without osteoporosis and osteopenia (p < .01)
- Statistically significant vs. group without osteoporosis and osteopenia (p < .05)
DISCUSSION
The bone loss may occur in about 25
to 30 percent of SLE patients [10]. Gcs
treatment is thought to be the main cause
of bone loss in SLE and its effect is dose
dependent [11-13]. Moreover, the degree
of bone loss is also connected with the
course of SLE as a consequence of the
activity of the inflammatory process. The
changes are found especially in trabecular
bone and to lesser degree in cortical bone
[14]. The most important and the most
serious results of osteoporosis are frac-
tures. The risk of fractures is determined
by peak bone mass, which people reach in
their twenties [15] and which is influenced
by hormonal function, diet, and some envi-
ronmental factors [16, 17]. In SLE, frac-
tures are observed less frequently than in
some other rheumatic conditions, e.g.,
rheumatoid arthritis
Glucocorticoids inhibit bone forma-
tion by blocking proliferation ofosteoblasts.Korczowska etal.: Glucocorticoids, bone metabolism, and systemic lupus 53
They also intensify the osteoclast activity
[18]. The largest bone loss is observed dur-
ing the first six to 12 months of gcs thera-
py [19, 20]. The degree of bone loss
depends on the duration oftreatment, daily
and total dose of gcs and the way of gcs
administration (e.g., systemic or local,
continuous or alternate dosing). In our
SLE group, the gcs dosage was being
adjusted to disease activity and severity
and ranged from 0 to 60 mg daily for a
given patient. Thus, gcs dosage profile
over time may have some influence on the
degree ofbone loss in individual patients.
In the investigated group of SLE
patients the changes in BMC and BMD
were not significant in comparison to con-
trol. However, the statistical analysis of
correlation between BMC and age showed
slightly accelerated bone loss in the patient
group (Figure 1). This matches well with
previous observations [21, 22]. Several
recent studies have convincingly demon-
strated that BMD measured in vertebral
region and distal forearm was not signifi-
cantly different in SLE compared to
healthy subjects. However, a decrease in
BMD was observed in femoral neck of
SLE patients. Moreover, no correlation
between BMD and the gcs dosage was
found [22-24].
The levels ofbone formation markers
(BGP, AP, AP-B, and PIPC) were not sig-
nificantly different in comparison to con-
trols. However, the bone resorption was
escalated. The levels of two (CTx,
Ca/Crea) of three analyzed parameters
were increased. Itis in agreement withearlier
studies, which confirmed a link between
osteoporosis and increased bone resorption
in SLE, while bone formation is only
slightly decreased or even normal [22].
Levels of IL-6 and TNF-a were ele-
vated in SLE, as it was previously
described [3, 17, 25]. It has been suggested
that serum TNF-a may be used as a marker
of the SLE activity [26] and its perfor-
mance is comparable to the SLEDAI
(Systemic Lupus Erythematosus Disease
Active Index). We did not find any signifi-
cant relationship between the decrease in
BMC/BMD in our SLE group in relation to
cytokine activity. Cytokine activity has an
important impact on bone turnover. It is
known that proinflammatory cytokines
like TNF-a or IL-I are the most potent
stimuli of bone resorption, and that gcs
strongly restrain the cytokine synthesis
[27]. In SLE, the inhibitory effect of gcs
treatment on activity of proinflammatory
cytokines may counterweigh its deleteri-
ous impact on the osteoblast/osteoclast
functions.
Our results suggest that osteoporosis
does not seem to be a frequent complica-
tion of long-term gcs treatment in SLE
despite the increased bone resorption.
Thus, long-term gcs treatment appears safe
with respect to bone metabolism in
patients with SLE.
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